Why the Invion share price zoomed 86% higher today

The Invion Ltd (ASX:IVX) share price almost doubled in value this morning after releasing an update on IVX-P02…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best performers on the Australian share market on Tuesday has been the Invion Ltd (ASX: IVX) share price.

In morning trade the clinical-stage drug development company's shares zoomed an incredible 86% higher to 2.6 cents.

Its shares have since given back a good portion of these gains, but are still trading 36% higher in early afternoon trade.

Why did the Invion share price rocket higher?

This morning the company announced that its research partner, the Hudson Institute of Medical Research, has completed the initial in vivo experiments in animal models to examine the uptake, localisation, and clearance from tumour tissue of Invion's photosensitiser, IVX-P02.

According to the release, a highlight of the in vivo testing was the demonstrated uptake of IVX-P02 in circulating tumour cells (CTCs). CTCs are cells that have shed from a primary tumour and are carried around the body in the blood.

This finding could be significant as it suggests that IVX-P02 may have an application in the treatment of metastatic cancer (cancer that has spread from the primary site of origin to different areas of the body).

Dr Andrew Stephens, the group head of the Ovarian Cancer Biomarkers Research Group at the Hudson Institute, appeared to be encouraged by the findings.

He said: "This is the first time that photosensitiser accumulation in CTCs has been demonstrated in vivo. The data suggests the potential application of IVX-P02 for haematological cancers in addition to solid tumours, as well as in therapies designed to prevent recurrence."

Before adding: "This new development is in its early stages, but it could lead to the development of a less harsh treatment for patients with metastatic cancer. The important thing is that IVX-P02 is taken up selectively by cancer cells and is not retained in any of the other organs, and in the blood it is taken up selectively by circulating cancer cells and not by red blood cells."

Another bonus was that the in vivo data also showed that injected IVX-P02 cleared rapidly from circulation, with around 90% of it gone within 30 minutes and then largely undetectable after two hours. Increasing doses up to 10mg/kg had no influence on the clearance rate.

Furthermore, there was no toxicity noted for any dose of IVX-P02 tested, nor was there any evidence of retention in any other organs, including the liver, kidney, spleen, ovaries, fallopian tube, lung, heart, brain or intestine.

Invion expects to start human trials of IVX-P02 for the treatment of skin cancer in the next quarter.

Elsewhere in the industry today, the Telix Pharmaceuticals Ltd (ASX: TLX) share price has edged higher after providing an update on its prostate imaging program and the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has given back its early gains and dropped lower after releasing an iPPS update.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Piggybank with an army helmet and a drone next to it, symbolising a rising DroneShield share price.
ETFs

VanEck Global Defence ETF up 31% since November as defence spending ramps up

As most investors would be aware, it's been a rough few months for the stock market. Since the start of…

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why A2 Milk, Orthocell, QBE, and Ramelius shares are pushing higher today

These shares are having a strong finish to the week. But why?

Read more »

a woman in a business suit holds a large solid gold bar in both hands with a superimposed image of a gagged gold line tracking upwards and featuring a swooping curved arrow pointing upwards.
Gold

ASX gold shares rally on another fresh record for the gold price

This corner of the market is dominating today.

Read more »

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an unhappy Thursday for ASX investors.

Read more »

Delighted adult man, working on a company slogan, on his laptop.
Technology Shares

Up 38% in 2025, why this ASX 200 tech stock could surge another 39%!

A top broker expects more strong outperformance from this surging ASX 200 tech stock.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Core Lithium, Healius, Neuren, and Reject Shop shares are storming higher today

These shares are avoiding the market weakness on Thursday. But why?

Read more »

Woman holding gold bar and cheering.
Gold

Up 50% in a month, why is this ASX All Ords gold stock surging again on Thursday?

The ASX All Ords gold miner is surging on Thursday even as the market sinks. But why?

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a big session for ASX shares this hump day.

Read more »